NewAmsterdam Pharma Company N.V.
NAMS
Jodie situation report
NewAmsterdam Pharma Company N.V.'s move is being confirmed by its market group.
NAMS accounts for 4.5% of the group's measured movement across 8.4 effective names. raw member direction is mixed; 8 of 12 session-normalized paths align to the upside. Capital-flow agreement is 17%, so confirmation is not yet clean. No verified headline preceded the measured group move.
Is this move genuinely shared?
No material onset for NAMS could be timestamped inside the aligned 5-minute window.
14 of 18 members in Biotech Rare Diseases are active. 0 of 1 disclosed connections are confirming.
- At least 12 of 18 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- A filing-linked outsider such as ROIV begins moving with the group.
Invalidation: The live read weakens if participation falls to 6 of 18 members or fewer.
Who this business touches
The relationships behind NAMS
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 1 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
NAMS is currently a Participant in the organic co-movement group Biotech Rare Diseases. This group is discovered from market behaviour rather than assigned from an industry taxonomy. No verified filing-linked names are available yet.